Hypothalamic Obesity and Insulin: Lustig's Clinical Research

Dr. Robert H. Lustig is a pediatric endocrinologist and neuroendocrinologist, now emeritus professor of pediatrics (endocrinology) at the University of California, San Francisco (UCSF), whose public fame rests on his arguments about sugar and fructose — but whose clinical research began with a much rarer problem: children who became severely obese after their brains were damaged by a tumour or by the treatment that cured it.

This page follows that work in plain language, as his papers state it: what hypothalamic obesity is, his years caring for brain-tumour survivors at St. Jude Children’s Research Hospital in Memphis, the 2003 study of who is most at risk, the mechanism he proposed (a brain that senses starvation and a vagus nerve that drives the pancreas to release too much insulin), his studies of the insulin-lowering drug octreotide in children and then in adults, the stimulant case series he co-authored, and the newer treatments that other research groups have since tested. It closes with how, in his own account, this narrow clinical problem led him to his broader ideas about insulin and the obesity epidemic.

Table of Contents

  1. 1. What Hypothalamic Obesity Is
  2. 2. The St. Jude Years and the Children He Treated
  3. 3. Who Is Most at Risk: The 2003 Brain-Tumour Survivor Study
  4. 4. How Lustig Explains the Weight Gain
  5. 5. The 1999 Octreotide Pilot Study
  6. 6. The 2003 Placebo-Controlled Octreotide Trial
  7. 7. From Brain-Injured Children to Adults With High Insulin
  8. 8. Adrenergic Drugs and the Dextroamphetamine Case Series
  9. 9. Later Treatments Studied by Other Research Groups
  10. 10. How This Work Shaped His Wider Ideas
  11. Key Research Papers
  12. Connections

1. What Hypothalamic Obesity Is

The hypothalamus is a small region at the base of the brain that keeps the body’s internal settings in balance: body temperature, thirst, sleep and wake cycles, the release of hormones from the pituitary gland, and the balance between the energy a person takes in and the energy the body burns. It does this partly by reading hormone signals from the rest of the body — above all leptin, the hormone released by fat tissue that reports how much fat the body has stored.

When this region is damaged, a distinctive kind of weight gain can follow. A 2012 review by an international group that included Lustig, written after a symposium at the European Congress of Obesity in Istanbul, describes hypothalamic obesity as “an intractable form of obesity syndrome” that was first described in people with hypothalamic tumours and surgical damage. The definition has since widened to include obesity after brain infections, injuries, problems with blood vessels, infiltrating diseases and hydrocephalus (fluid build-up in the brain). The review lists the ways damage to the ventromedial part of the hypothalamus leads to weight gain: overeating, a low resting metabolic rate, an imbalance in the autonomic (automatic) nervous system, shortages of growth hormone, the sex-gland-stimulating hormones and thyroid-stimulating hormone, reduced movement, and poor sleep.

A 2024 clinical overview by Christian Roth and Shana McCormack describes the same condition as “a rare and complex disorder that confers substantial morbidity and excess mortality.” It explains that acquired forms follow tumours that affect the hypothalamus — the most common being craniopharyngioma, a slow-growing, non-cancerous tumour near the pituitary gland — or the surgery or radiation used to treat them, or other injuries to the region. Damage to these nuclei, the overview says, often leads to constant hunger, resistance to insulin and leptin inside the brain, lower activity of the sympathetic (“fight or flight”) nervous system, low energy expenditure and more energy stored as fat, “the collective effect of which is rapid weight gain.” People with this hunger, the overview notes, do not feel full at the end of a meal.

Lustig’s own 2011 review, focused on survivors of craniopharyngioma, reports that obesity occurs in up to 75% of them, and that the weight gain is “unlike that of normal obesity, in that it occurs even with caloric restriction.”

Back to Table of Contents

2. The St. Jude Years and the Children He Treated

Before joining UCSF in 2001, Lustig worked at the University of Tennessee in Memphis and at St. Jude Children’s Research Hospital, which treats children with cancer. His own biography describes the work there: he “was charged with the endocrine care of many children whose hypothalami had been damaged by brain tumors, or subsequent surgery, radiation, or chemotherapy. Many patients who survived became massively obese.”

These were children who had survived serious illness, often after years of treatment, only to face relentless weight gain that dieting did not stop. His papers from this period list his affiliation as the Department of Pediatrics, University of Tennessee, Memphis (1999), and the Department of Endocrinology, St. Jude Children’s Research Hospital (2003). He trained in neuroendocrinology — the study of how the brain controls hormones — and his biography describes that training as being in “hypothalamic development, anatomy, and function.”

The St. Jude group also documented how cancer treatment itself can disturb the hypothalamus. In a 2004 paper led by endocrinologist Susan Rose, with Lustig as a co-author, the team reviewed the records of 362 childhood cancer patients who had been referred for full hormone testing because of altered growth or development after treatment (1987–2002). Of these, 31 had received chemotherapy without any radiation to the head or whole body and had no brain tumour. In that group, growth hormone deficiency was found in 15 (48%) and central hypothyroidism (low thyroid hormone because the brain under-signals the thyroid) in 16 (52%); overall, 81% had at least one of the hormone problems studied. The authors stress that this was not a measure of how common the problem is, but an evaluation of children already referred, and they conclude that hypothalamic dysfunction “may occur in survivors of non-CNS tumors who receive chemotherapy but do not receive cranial irradiation.”

Back to Table of Contents

3. Who Is Most at Risk: The 2003 Brain-Tumour Survivor Study

To find out which children were most likely to develop this kind of obesity, Lustig and colleagues went back through the body mass index (BMI) growth curves of St. Jude’s brain-tumour patients diagnosed between 1965 and 1995. They included only children who were diagnosed before age 14, could walk, had no spinal cord involvement, had not received high-dose hydrocortisone replacement, were treated and followed at St. Jude, and had survived free of disease for more than five years — 148 children in all. The study, published in 2003 in the Journal of Clinical Endocrinology and Metabolism, was a retrospective review of records, not a trial.

The team examined many possible risk factors: age at diagnosis, where the tumour sat, its type, how much was removed by surgery, whether a shunt was needed to drain fluid from the brain, early high-dose steroid treatment, radiation to the head and the exact radiation dose reaching the hypothalamus, chemotherapy given into the spinal fluid, and the presence of hormone problems.

The factors linked to obesity were:

The authors write that the results “verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors,” and that hypothalamic radiation doses of more than 51 Gy “are permissive.” They add that the findings provide risk-assessment criteria for preventive measures before obesity develops in children at risk.

The St. Jude follow-up continued for decades. In 2022 radiation oncologist Thomas Merchant and colleagues, with Lustig as senior author, reported long-term hormone outcomes in 101 children with craniopharyngioma treated with limited surgery and conformal radiation (54 Gy, shaped tightly to the tumour) beginning in 1998. Hormone deficiencies were common: the 10-year cumulative incidence of growth hormone deficiency was 68% in Black patients and 94% in white patients, and deficiencies of thyroid-stimulating hormone, adrenal-stimulating hormone and the sex-gland-stimulating hormones were frequent too, linked to host, tumour and treatment factors. Body mass index before radiation was higher in white patients who already had diabetes insipidus (a hormone-related loss of water through the kidneys) or growth hormone deficiency.

Back to Table of Contents

4. How Lustig Explains the Weight Gain

Lustig’s explanation of hypothalamic obesity runs through his papers and his own biography. In his account, the damaged hypothalamus can no longer read the leptin signal from fat tissue. His biography says this led to “the inability to sense the hormone leptin, which in turn, led to the starvation response.” However much fat the body actually carries, the brain behaves as if it is starving.

His 2011 review sets out the steps:

Insulin is the hormone that moves sugar out of the blood and directs energy into storage, including fat storage. Lustig’s argument is that in these children the pancreas is being told by the vagus nerve to release too much insulin, and that this excess insulin pushes incoming energy into fat cells, leaving less available for the rest of the body. He set out this idea in a 2003 paper titled “Autonomic dysfunction of the beta-cell and the pathogenesis of obesity” (beta cells being the insulin-producing cells of the pancreas). The 2003 St. Jude trial report summarises the same view: these children “are thought to exhibit autonomic dysregulation of the beta-cell, with insulin hypersecretion in response to oral glucose tolerance testing.”

From this mechanism he drew a conclusion about diet and exercise in this group. His 2011 review states that “attempts at lifestyle modification are useless to prevent or treat the obesity” and calls lifestyle intervention “essentially useless in this syndrome” — his description of a condition in which the brain’s starvation signal does not respond to eating less. He lists the drug approaches that had been tried: adrenergic drugs to mimic the lost sympathetic activity, suppression of insulin release with octreotide, or both. He also notes that bariatric surgery — Roux-en-Y gastric bypass, laparoscopic gastric banding and truncal vagotomy (cutting the main trunks of the vagus nerve) — had been attempted “with variable results,” and concludes that “early and intensive management is required.”

The reasoning behind his drug choice follows directly from the mechanism: if too much insulin is driving the weight gain, then lowering insulin release would slow it. That is what he set out to test.

Back to Table of Contents

5. The 1999 Octreotide Pilot Study

Octreotide is a man-made version of somatostatin, a natural hormone that, among other actions, damps down the release of insulin from the pancreas. It is used in medicine for several hormone-producing tumours and for acromegaly. Lustig chose it because, in his model, it would block the excess insulin release that the overactive vagus nerve was driving.

His first study, published in the Journal of Pediatrics in 1999, opened by noting that in rodents, damage to the ventromedial hypothalamus causes overeating, obesity, high insulin and insulin resistance, and that reducing insulin secretion in humans “may attenuate weight gain.” The study enrolled eight children with severe, hard-to-treat obesity after treatment for leukaemia or brain tumours. Each child had an oral glucose tolerance test, with insulin measured at the same time, before and after six months of octreotide. Each child’s six months on the drug was compared with the six months of observation before the study — there was no separate placebo group.

The results reported in the abstract:

The authors concluded that “patients with hypothalamic obesity demonstrate excessive insulin secretion,” and that the results “suggest that normalization of insulin secretion may be an effective therapeutic strategy in this syndrome.” Lustig’s biography recalls what he saw clinically: with octreotide “he was able to get them to lose weight; but more remarkably, they started to exercise spontaneously.”

Back to Table of Contents

6. The 2003 Placebo-Controlled Octreotide Trial

A small before-and-after study cannot rule out chance or the effect of extra attention, so the St. Jude team next ran a randomised, double-blind, placebo-controlled trial — one in which neither the families nor the researchers knew who was receiving the real drug. It was published in the Journal of Clinical Endocrinology and Metabolism in 2003.

Eighteen young people with hypothalamic obesity took part. At the start they weighed an average of 100.6 kg, with an average body mass index of 37.1. They received either octreotide, injected under the skin at 5 to 15 micrograms per kilogram of body weight per day, or a placebo, for six months.

The reported results:

On safety, the authors report that “complications and adverse events were mild and self-limited” and that octreotide “was safe and well tolerated” in this trial. Their summary: “Octreotide suppressed insulin, and stabilized weight and BMI. Improved quality of life correlated with the degree of insulin suppression.” In other words, the children on the drug still gained a little weight on average, but far less than those on placebo.

The parent-reported rise in activity matched what Lustig had noticed in the pilot study. In his reading, it fitted the model: once less energy is being forced into fat storage, more is available to the rest of the body, and the children move more of their own accord.

Back to Table of Contents

7. From Brain-Injured Children to Adults With High Insulin

Lustig then asked whether the same insulin-driven pattern could be found in people whose brains had not been injured. His biography says he went on to show “the same phenomenon in obese adults without CNS lesions.” Two adult studies used a long-acting injectable form of octreotide, given once every four weeks (octreotide LAR).

The 2004 leptin study

In a 2004 paper in the International Journal of Obesity, Lustig and colleagues followed 17 adults with obesity treated with octreotide LAR, 40 mg by intramuscular injection every 28 days for six months. Six of them lost more than 10% of their body weight, with a 34% fall in leptin and a 46% fall in insulin output during a glucose tolerance test; they kept their resting energy expenditure unchanged. The other eleven showed little change. The authors used the ratio of resting energy expenditure to leptin as a rough marker of how sensitive a person is to leptin. They concluded that the results “support the possibilities that hyperinsulinemia may be a proximate cause of leptin resistance, and that reduction of insulinemia may promote weight loss by improving leptin sensitivity.” This was a single-group study without a placebo comparison.

The 2006 multicentre trial

The larger test was a multicentre, randomised, double-blind, placebo-controlled, dose-finding trial published in the International Journal of Obesity in 2006, with Lustig as first author. It enrolled 172 adults (28 men and 144 women) with a body mass index between 30 and 65 and evidence of insulin hypersecretion (releasing more insulin than usual after a glucose drink). Their average age was 38 and average weight 110.7 kg. They received octreotide LAR at 20, 40 or 60 mg, or placebo, for six months.

Safety facts reported in the trial: the most common adverse events were diarrhoea, headache, gallstones (cholelithiasis), nausea and abdominal pain. Blood glucose during the glucose tolerance test was higher on octreotide LAR than on placebo (an increase of 39 to 40 mg/dl·h in the area under the curve), consistent with the drug’s known action of lowering insulin release. The authors describe the safety profile as “consistent with the known effects of octreotide from previous studies.”

Back to Table of Contents

8. Adrenergic Drugs and the Dextroamphetamine Case Series

The other half of Lustig’s mechanism is the drop in sympathetic nerve activity, which he links to low energy and low energy expenditure. His 2011 review lists adrenergic drugs — medicines that mimic the sympathetic nervous system’s chemical messengers — as one way to address it.

In 2019 he was a co-author of a case series from the University Medical Center in Ulm, Germany, led by pediatric endocrinologist Christian Denzer, published in Obesity Facts. It reported every patient started on dextroamphetamine (a stimulant medicine that acts on both the brain and the peripheral nervous system) for severe hypothalamic obesity at that clinic between 2010 and 2013. Dextroamphetamine was started at 5 mg once a day and adjusted up to 20 mg a day according to response.

The authors conclude that dextroamphetamine “led to stabilization or reduction of BMI z-score” in these seven patients, and that, given the expected rise in weight in the natural course of the disease, the findings “are promising and warrant further study.” A case series has no comparison group, so it describes what happened to these patients rather than proving the drug caused the change.

A larger Dutch cohort, 2022

A later report from two Dutch academic clinics in Utrecht and Rotterdam (van Schaik and colleagues, without Lustig) described 19 children with hypothalamic obesity, average age 12.3, treated off-label with dextroamphetamine. Of the 17 who could be evaluated after an average of about two years, 14 responded with a fall or stabilisation of body mass index, while body mass index rose in three. In 11 responders, measured resting energy expenditure rose by 8.9% relative to the predicted value, and 13 patients (68%) reported less excessive hunger, more energy or better behaviour. Safety fact: two patients developed high blood pressure during treatment, which led to a dose change or stopping the drug. The authors note that no drug was approved for children with hypothalamic obesity at the time.

Back to Table of Contents

9. Later Treatments Studied by Other Research Groups

Since Lustig’s octreotide studies, other research groups have tested drugs that act on different parts of the appetite system. These studies did not involve Lustig; they are described here as later research on the same condition.

Setmelanotide

The hypothalamus controls appetite partly through the melanocortin-4 receptor, a switch that, when activated, signals fullness. Setmelanotide is a drug that activates this receptor. In a phase 2, open-label trial (everyone received the drug; there was no placebo group) at five centres in the United States, published in The Lancet Diabetes and Endocrinology in 2024 and led by Christian Roth, 18 patients aged 6 to 40 with hypothalamic obesity after injury or after treatment of a non-cancerous tumour affecting the hypothalamus received setmelanotide, increased up to 3.0 mg by daily injection under the skin, for 16 weeks. The trial was funded by the drug’s manufacturer.

Glucagon-like peptide-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) is a gut hormone that promotes fullness, and drugs that mimic it are widely used for type 2 diabetes and obesity. A 2024 review by Paul Dimitri and Christian Roth in the Journal of the Endocrine Society notes that GLP-1 acts through brain pathways that are partly independent of the hypothalamus, which is why these drugs have been tried in hypothalamic obesity. The review found 7 case studies, 5 case series and 2 published clinical trials. All the case studies reported weight loss; the case series were variable, some showing no weight loss and others moderate to substantial loss. In one trial, nearly half the participants randomised to weekly exenatide had a reduced body mass index, and, unexpectedly, body mass index fell more in those with more extensive hypothalamic injury. The authors conclude that these drugs “potentially offer a new approach” and that further randomised trials are needed.

Where the field stands

The 2024 overview by Roth and McCormack sums up the history: “To date, most efforts to treat HO have been disappointing and met with limited, if any, long-term success” (HO standing for hypothalamic obesity), adding that new treatments based on the condition’s distinct biology “may hold promise for the future.”

Back to Table of Contents

10. How This Work Shaped His Wider Ideas

Lustig describes his hypothalamic-obesity work as the starting point for everything that followed. On his own site he traces a path from his St. Jude patients to a “unifying hypothesis” about the obesity epidemic, and from there to “the specific role of fructose (half of sucrose and high-fructose corn syrup) as a specific mediator of both chronic disease, and continued caloric consumption.”

The link, in his account, is insulin and leptin. In children with damaged hypothalami, the brain cannot read leptin, behaves as if starving, and high insulin drives energy into fat. His 2004 adult study suggested to him that high insulin might itself block the leptin signal in people without brain injury. In a 2006 paper titled “Childhood obesity: behavioral aberration or biochemical drive? Reinterpreting the First Law of Thermodynamics,” he argues that the behaviours usually blamed for obesity — eating more and moving less — “are secondary to obligate weight gain,” driven by high insulin through the steering of energy into fat, interference with leptin signalling and interference with the fading of food reward.

That chain of reasoning — from a rare brain injury, to insulin, to leptin, to the everyday diet — underlies his later lecture Sugar: The Bitter Truth, his fructose-restriction study in children, and his books on processed food. Those subjects are covered on the other pages about him on this site, linked below.

Back to Table of Contents

Key Research Papers

  1. Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr. 1999;135(2 Pt 1):162-8. — PubMed PMID: 10431109
  2. Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003;88(2):611-6. — PubMed PMID: 12574189
  3. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586-92. — PubMed PMID: 12788859
  4. Lustig RH. Autonomic dysfunction of the beta-cell and the pathogenesis of obesity. Rev Endocr Metab Disord. 2003;4(1):23-32. — PubMed PMID: 12618557
  5. Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab. 2004;17(1):55-66. — PubMed PMID: 14960022
  6. Lustig RH, Sen S, Soberman JE, Velasquez-Mieyer PA. Obesity, leptin resistance, and the effects of insulin reduction. Int J Obes Relat Metab Disord. 2004;28(10):1344-8. — PubMed PMID: 15314628
  7. Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006;30(2):331-41. — PubMed PMID: 16158082
  8. Lustig RH. Childhood obesity: behavioral aberration or biochemical drive? Reinterpreting the First Law of Thermodynamics. Nat Clin Pract Endocrinol Metab. 2006;2(8):447-58. — PubMed PMID: 16932334
  9. Lustig RH. Hypothalamic obesity: causes, consequences, treatment. Pediatr Endocrinol Rev. 2008;6(2):220-7. — PubMed PMID: 19202508
  10. Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Front Endocrinol (Lausanne). 2011;2:60. — PubMed PMID: 22654817
  11. Bereket A, Kiess W, Lustig RH, Muller HL, Goldstone AP, Weiss R, et al. Hypothalamic obesity in children. Obes Rev. 2012;13(9):780-98. — PubMed PMID: 22577758
  12. Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M. Treatment of hypothalamic obesity with dextroamphetamine: a case series. Obes Facts. 2019;12(1):91-102. — PubMed PMID: 30844799
  13. Merchant TE, Edmonston DY, Wu S, Li Y, Boop FA, Lustig RH. Endocrine outcomes after limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol. Neuro Oncol. 2022;24(12):2210-2220. — PubMed PMID: 35481829
  14. van Schaik J, Welling MS, de Groot CJ, van Eck JP, Juriaans A, Burghard M, et al. Dextroamphetamine treatment in children with hypothalamic obesity. Front Endocrinol (Lausanne). 2022;13:845937. — PubMed PMID: 35355559
  15. Roth CL, McCormack SE. Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab. 2024;26 Suppl 2:34-45. — PubMed PMID: 38450938
  16. Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380-389. — PubMed PMID: 38697184
  17. Dimitri P, Roth CL. Treatment of hypothalamic obesity with GLP-1 analogs. J Endocr Soc. 2024;9(1):bvae200. — PubMed PMID: 39703362

PubMed Topic Searches

  1. Hypothalamic obesity and octreotide
  2. Craniopharyngioma, obesity and hypothalamic damage
  3. Lustig RH and hypothalamic research
  4. Hypothalamic obesity: setmelanotide and GLP-1 drugs

Further Reading

Back to Table of Contents

Connections